Boston continues to cement its reputation as one of the most dynamic hubs for technology, biotech, and health innovation. In 2025, a wave of Series C funding rounds highlighted the city’s ability to attract capital, nurture bold ideas, and create companies with global impact.
These rounds not only injected millions into local startups but also reinforced Boston’s position as a place where investors see tangible opportunities for growth and resilience.
Here, we examine nine Boston companies that secured Series C rounds this year. By presenting the amounts raised, the industries they represent, the investors who joined, and the strategic goals tied to these financings, we gain a comprehensive picture of the region’s innovation ecosystem.
SportsVisio — $3.2M
SportsVisio may have secured the smallest Series C on this list, but the $3.2 million it added to its total funding represents a strategic step forward. The company specializes in AI-driven video analysis for sports such as basketball and volleyball, turning raw footage into real-time stats and highlights.
Backed by Sapphire Sport, Hyperplane Ventures, and newcomers like Mighty Capital and Sony Innovation Fund, SportsVisio shows how even modest amounts of capital can unlock significant opportunities in niche markets.
The funding will support the company’s expansion into additional sports, especially youth and amateur baseball.
By focusing on grassroots adoption, SportsVisio positions itself as more than a tool for professionals—it becomes an enabler for leagues and coaches everywhere who need affordable performance insights. This democratization of sports technology speaks to a broader trend of making high-quality analytics accessible beyond elite teams.
Boston’s vibrant AI and data ecosystem provides fertile ground for SportsVisio to grow. With universities, sports franchises, and tech incubators all nearby, the company benefits from a unique intersection of talent and demand.
This combination ensures that SportsVisio can use its new resources to reach audiences previously excluded from advanced sports analytics.
Blockskye — $15.8M
Blockskye stands at the crossroads of blockchain technology and corporate travel. Its $15.8 million Series C round, led by Blockchange Ventures with support from United Airlines Ventures and Lightspeed Faction, underlines how traditional industries are ready to modernize.
The company’s platform streamlines booking, payments, and expense reporting by eliminating outdated processes that frustrate business travelers and finance teams alike.
The new capital will help Blockskye expand globally and launch new payment-focused products. As multinational corporations struggle with rising travel costs and compliance requirements, the company’s solution offers transparency and efficiency.
This is not only about saving money but also about building trust in how travel data and expenses are managed. By leaning into blockchain’s ability to create immutable records, Blockskye aims to set a new standard for corporate travel.
Boston provides the right environment for such innovation. With a concentration of finance professionals, global companies, and travel-heavy industries, the city offers a natural customer base.
By combining capital efficiency with cutting-edge technology, Blockskye illustrates how even legacy industries like travel can undergo transformation when paired with vision and investment.
Tive — $40M
Tive secured a $40 million Series C in early 2025, highlighting the urgency for real-time supply chain monitoring. Led by World Innovation Lab and Sageview Capital, with additional backing from Qualcomm Ventures, RRE Ventures, and others, the round reflects investor recognition of logistics as a strategic frontier.
Tive’s technology provides shippers and retailers with real-time tracking of goods using advanced sensors and an AI-driven platform.
The funding will enable Tive to expand globally, develop new tracker devices, and integrate AI features into its platform.
By doing so, the company addresses a pain point that became especially visible during pandemic disruptions: the lack of transparency in supply chains. With Tive, companies gain not only visibility but also predictive insights that help them avoid costly delays.
As Boston continues to foster companies that combine hardware innovation with software intelligence, Tive exemplifies this hybrid strength.
Its commitment to building sustainable supply chain solutions also resonates with global environmental priorities. With this round, the company positions itself to remain a key partner in solving one of the world’s most complex logistical challenges.
CloudZero — $56 Million
In May 2025, CloudZero announced a $56 million Series C, led by BlueCrest Capital Management and Innovius Capital.
With additional backing from Matrix Partners, Threshold Ventures, and MongoDB, the funding reflects the increasing importance of financial operations within cloud computing. CloudZero helps enterprises track, analyze, and optimize their cloud spending.
The funds will accelerate development of AI-driven forecasting tools, create deeper integration between engineering and finance, and expand partnerships with cloud providers.
By embedding cost insights directly into workflows, CloudZero empowers engineering teams to make decisions aligned with financial goals. This represents a shift from reactive budgeting to proactive cost management.
Boston’s vibrant cloud and software ecosystem offers CloudZero access to talent and customers eager for cost visibility. With cloud adoption continuing to rise, the company’s solution becomes indispensable for businesses balancing performance with expenses.
The Series C enables CloudZero to refine its vision of a future where financial discipline and innovation coexist.
Eleos Health — $60M
Boston has long been a leader in healthcare innovation, and Eleos Health adds to that legacy with a $60 million Series C.
The round, led by Greenfield Partners and supported by F-Prime Capital, Menlo Ventures, and others, reflects the growing importance of technology in behavioral health. Eleos leverages AI to reduce documentation time for clinicians, allowing them to spend more moments with patients.
The fresh funding will support product expansion and market penetration, with a special emphasis on substance use disorder centers.
By targeting underserved areas of behavioral healthcare, Eleos demonstrates how capital can fuel not just growth but also social impact. Its AI “agents” streamline administrative tasks, helping providers address workforce shortages and improve care delivery.
Boston’s combination of academic expertise and healthcare infrastructure provides Eleos with an unparalleled environment for innovation.
The city’s strong network of hospitals and research institutions ensures that new solutions can be tested and refined quickly. This Series C represents a pivotal step toward making behavioral healthcare more accessible and efficient.
Ledgebrook — $65M
Ledgebrook raised $65 million in Series C funding in June 2025, positioning itself as a disruptor in the insurance sector
The round was led by Stephens Group with participation from Duquesne Family Office, Brand Foundry, and others. By focusing on wholesale brokers in the excess and surplus market, Ledgebrook addresses an often-overlooked segment of the insurance industry.
The capital will allow Ledgebrook to broaden its offerings, automate underwriting, and assume more risk directly. These steps will help brokers and carriers handle policies faster and with more accuracy. This approach places Ledgebrook at the heart of an industry under pressure to innovate while maintaining trust.
Boston’s finance and insurance heritage makes it a logical base for this type of company. With this Series C, Ledgebrook strengthens the city’s profile as a home for financial technology startups that address specific market inefficiencies.
The company’s mission to simplify complex processes resonates with a broader movement toward transparency and efficiency.
Cohere Health — $90M
Cohere Health raised $90 million in May 2025 to push forward its mission of reinventing prior authorization in healthcare.
Temasek led the round, with Deerfield Management, Flare Capital, and Polaris Partners participating. Cohere’s “Unify” platform uses AI and clinical intelligence to streamline communications between providers and payers.
The new funds will be invested in expanding Unify, developing new clinical use cases, and hiring additional engineering and sales talent.
Cohere aims to reduce delays in patient care by simplifying the approval process, turning what was once a bottleneck into a more seamless workflow. The strategic goal is clear: bring efficiency and empathy to a system often criticized for slowing treatment.
Boston’s leadership in digital health makes it an ideal headquarters for Cohere. With close proximity to both world-class hospitals and forward-thinking investors, the company benefits from a supportive ecosystem. Its Series C funding sets the stage for scaling a platform that can redefine a critical part of healthcare delivery.
Odyssey Therapeutics — $101M
Odyssey Therapeutics closed a $101 million Series C in 2025, underscoring Boston’s strength in biotech.
Led by Ascenta Capital with support from OrbiMed, SR One, and General Catalyst, the round equips Odyssey with resources to advance its immunology and oncology programs. The company focuses on next-generation therapeutics aimed at complex diseases.
The funding will move multiple candidates into clinical trials while sustaining the discovery pipeline. By balancing late-stage progress with ongoing research, Odyssey ensures that innovation remains constant. Investors’ confidence highlights both the potential of its drug candidates and the robustness of Boston’s biotech ecosystem
Boston continues to dominate in life sciences, and Odyssey adds another chapter to this story. By combining scientific rigor with significant capital, the company enhances the city’s reputation as a global biotech powerhouse. This Series C reflects both market confidence and scientific potential that could impact patients worldwide.
Harrison.ai — $112M
Harrison.ai, though originally from Australia, established a Boston office and raised $112 million in Series C funding in early 2025. The round was co-led by Aware Super and Evergreen Coast Capital, alongside Horizons Ventures and Blackbird Ventures.
By choosing Boston as a base for expansion, Harrison.ai signals the city’s global influence in healthtech.
The funds will accelerate development of AI products for medical imaging and support hiring engineers and clinical experts in Boston. This growth strengthens the company’s ability to serve hospitals worldwide with AI-driven diagnostic tools.
The capital also enables Harrison.ai to expand partnerships with healthcare providers across the United States. Boston’s international reputation in healthcare and AI made it an attractive location for Harrison.ai’s growth.
With this Series C, the company not only reinforces Boston’s role in global health innovation but also highlights how the city draws companies from around the world. This round exemplifies how Boston remains a magnet for healthtech breakthroughs.
Boston’s Series C Momentum
The 2025 Series C funding rounds tell a compelling story of Boston’s role as a center of innovation.
From sports analytics to biotech, these companies illustrate how diverse sectors thrive in one city. Their funding achievements not only advance their missions but also solidify Boston’s place on the global map of entrepreneurial success.
Each of these companies reflects a commitment to solving complex problems with technology and creativity. The amounts raised show investor confidence in Boston’s ability to generate world-class solutions.
These success stories remind us that the city’s strength lies in its diversity of industries and its ability to integrate academic, financial, and technological resources.
The Boston startup ecosystem offers valuable lessons for other regions. It demonstrates how local ecosystems can align resources for global impact. The city’s 2025 Series C surge represents not only capital raised but also the future being built.
Contact us to learn more about our software development services, and follow us on LinkedIn for more tech trends.
FAQ
Which Boston company raised the largest Series C in 2025?
Harrison.ai, with its Boston office expansion, secured the largest Series C round at $112 million, aimed at scaling its AI-powered medical imaging solutions.
How much Series C funding did Odyssey Therapeutics raise?
Odyssey Therapeutics raised $101 million in 2025, with the goal of moving multiple drug candidates into clinical trials while continuing its discovery pipeline in oncology and immunology.
What makes Boston attractive for Series C investments?
Boston’s ecosystem blends world-class universities, hospitals, biotech research centers, and an active venture capital community. This combination creates an environment where companies can scale rapidly.
Which sectors dominated Boston’s Series C rounds in 2025?
Healthcare and biotech were the most prominent, with companies like Eleos Health, Cohere Health, and Odyssey Therapeutics leading the way. However, sectors like supply chain, insurance, travel tech, and sports analytics also saw significant activity
How do these Series C rounds impact Boston’s startup ecosystem?
They strengthen Boston’s reputation as a hub for innovation while providing the capital companies need to expand globally, hire talent, and bring products to market faster.
What role do investors play in shaping these companies’ futures?
Beyond providing capital, investors offer strategic guidance, industry connections, and credibility that help Boston companies enter new markets and refine their long-term growth strategies.
